Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced the closing of
its initial public offering of 6,000,000 shares of its common stock at a
public offering price of $14.00 per share, before underwriting discounts.
UBS Investment Bank and Wells Fargo Securities acted as joint
book-running managers for the offering. JMP Securities acted as lead
manager and Roth Capital Partners acted as co-manager for the offering.
A registration statement relating to the securities sold in this
offering has been filed wih and declared effective by the Securities
and Exchange Commission. A copy of the final prospectus for this
offering may be obtained from UBS Investment Bank, Attention: Prospectus
Department, 299 Park Avenue, New York, NY 10171, or by phone at
1-888-827-7275; or Wells Fargo Securities, Attention: Equity Syndicate
Department, 375 Park Avenue, New York, New York, 10152, or by email at email@example.com,
or by phone at 1-800-326-5897.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of, these
securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of such state or jurisdiction.
Concert Pharmaceuticals is a clinical stage biopharmaceutical company
focused on applying its DCE Platform® (deuterated chemical entity
platform) to create novel small molecule drugs. This approach starts
with approved drugs, advanced clinical candidates or previously studied
compounds that have the potential to be improved with deuterium
substitution to enhance clinical safety, tolerability and efficacy. The
company is developing a broad pipeline targeting CNS disorders, renal
disease, inflammation and cancer.
Concert Pharmaceuticals Inc., the CoNCERT Pharmaceuticals Inc. logo and
DCE Platform are registered trademarks of Concert Pharmaceuticals, Inc.
[ Back To NFVZone's Homepage ]